panitumumab,bevacizumab
takeda,amgen,roche
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'panitumumab', 'takedapharma', 'takeda']
 2022 updates:
the phase iii study sponsored by evaluating the panitumumab + mfolfox6 versus bev + mfolfox6 in mcrc patients as first-line treatment in patients with ras wild-type mcrc was presented at the #asco 2022. learn more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry